MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Contributed by: Business Wire

Logo

Tags

Biotechnology

Mental Health

Health

Pharmaceutical

Clinical Trials

Mind Medicine (MindMed) Inc.

More Like This

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Reports First Quarter 2024 Financial Results and Business Updates

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

MindMed Reports 2023 Financial Results and Business Updates

MindMed to Present at Upcoming May Medical Conferences